Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a $26 price target.
May 31, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals and maintained a $26 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $26 price target by a reputable analyst suggests a positive outlook for Phathom Pharmaceuticals. This could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100